Here's the short version. Pharmacies can't legally compound GHK-Cu for injection right now, so there are no prescription injections to get. The vials sold online are labeled for research, not for people. If skin is your goal, the creams and foams have a lawful route, and that's where this page points you.
| Form | FDA status | Lawful route | Source |
|---|---|---|---|
| Injectable (compounded) | Category 2 from September 29, 2023; nominations withdrawn April 22, 2026; now in FDA's "nominated but withdrawn" table | None | FDA 503A list, September 29, 2023 [2]; FDA safety-risks page, April 22, 2026 [3] |
| Non-injectable (compounded cream or foam) | Category 1, under evaluation; added back May 14, 2026 | Prescription filled by a licensed 503A pharmacy | FDA 503A list, May 14, 2026 [1] |
| Cosmetic skin care (copper tripeptide-1) | Cosmetic; no FDA approval needed if it makes no drug claims | Over the counter | FDA cosmetics guidance [6] |
| "Research use only" vial | Not a drug for people | None | Not applicable |
What FDA said about injectable GHK-Cu, and when
FDA placed injectable GHK-Cu in Category 2 in September 2023, citing possible immune reactions from peptide aggregation and impurities, and limited human safety data [3].
Category 2 is FDA's group for nominated substances that raise significant safety risks in compounding. FDA says it would consider acting against a compounder who uses a Category 2 substance [4]. FDA's own wording: injectable GHK-Cu "may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities." It adds that "there are limited data in humans" [3].
- September 29, 2023: FDA's 503A list puts GHK-Cu for injectable routes in Category 2, and GHK-Cu for other routes in Category 1 [2].
- April 22, 2026: the nominations for GHK-Cu are withdrawn. Injectable GHK-Cu leaves Category 2 and moves to FDA's "nominated but withdrawn" table [3].
- May 5, 2026: one nominator tells FDA it meant to withdraw only the injectable route [1].
- May 14, 2026: FDA adds GHK-Cu "except for injectable routes of administration" back to Category 1 [1].
Withdrawn doesn't mean cleared. A substance that isn't in Category 1 falls outside FDA's interim policy, so a pharmacy has no protected route to compound it [4].
Why the topical form is treated differently
FDA lists GHK-Cu "except for injectable routes of administration" as its own entry, and that entry sits in Category 1, under evaluation, as of May 14, 2026 [1].
Category 1 means a substance was nominated with enough information for FDA to evaluate it. While it does, FDA says it doesn't intend to act against a pharmacy compounding it, as long as the interim policy's conditions are met [4] [5]. In practice that means a compounded GHK-Cu cream or foam, prescribed by a licensed clinician and made by a licensed pharmacy.
There's also the cosmetic track. Cosmetics don't need FDA approval before they're sold. What makes a product a drug is its intended use: FDA's examples of drug claims include restoring hair growth and "regenerating cells" [6]. A copper-peptide serum sold for appearance is a cosmetic.
What to ask before you start any GHK-Cu prescription
Three questions sort a lawful prescription from everything else. Ask them before you pay.
- Is this a cream, foam or other topical? If the answer is an injection, there's no lawful compounding route for it.
- Which licensed pharmacy makes it, and is it a 503A pharmacy filling a prescription for you?
- Who's the clinician reviewing my intake, and how do I reach them if my skin reacts?
What "research use only" GHK-Cu vials are
Vials sold "for research use only" are not made or sold as drugs for people, so no prescriber, pharmacy or quality standard applies to what's inside.
Research-use vials are advertised online. A search listing, seller certificate or professional-looking page does not establish a lawful prescription product. Check the actual pharmacy and legal basis before paying:
- The product is labeled "not for human consumption" or "research use only."
- There's no clinician review or intake before checkout.
- No pharmacy is named, or the seller can't tell you which licensed pharmacy made it.
- The page offers injection guidance without a prescriber involved.
The same logic applies to other peptides sold this way. Ipamorelin and CJC-1295's legal status works through it for two more.
What you can get instead
If your goal is skin, the options with a lawful route are cosmetic copper-peptide products and prescribed compounded topical GHK-Cu.
Set expectations before you start. The human evidence for topical GHK-Cu is small: a small randomized post-laser trial found no objective change at 12 weeks, though users rated their skin better [7]. A 2026 systematic review calls the human literature "thin and fragmented" [8]. These pages go further:
- How long GHK-Cu takes to work, with selected clinical study time points.
- GHK-Cu for acne, and the treatments with real acne evidence.
- GHK-Cu for hair growth, and what each hair study actually tested.
- The skin shortlist, for programs with a lawful route.
What's still open
FDA says it intends to consult its Pharmacy Compounding Advisory Committee on GHK-Cu before the end of February 2027, so this status can change [1].
The committee advises FDA on whether a substance belongs on the 503A bulks list. Until FDA acts, the record above stands: topical in Category 1, injectable on no list that permits compounding. This page gets updated when that changes.